Boston takes urology company BEI for $95 million
This article was originally published in Clinica
Boston Scientific's spending spree shows no sign of letting up. With news of its Microheart deal still being digested (see Clinica No 1007, p 15), the company last week added uterine bleeding technology company BEI Medical Systems to its growing group of subsidiaries. Boston paid $95 million, or $6.84 per share for the company, a $1.32 premium on the May 13 closing price, but the price immediately exceeded by $0.26 the purchase price on day one of trading.
You may also be interested in...
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.